Dynamic changes in cerebral and peripheral markers of glutamatergic signaling across the human sleep-wake cycle by Weigend, Susanne et al.








Dynamic changes in cerebral and peripheral markers of glutamatergic
signaling across the human sleep-wake cycle
Weigend, Susanne ; Holst, Sebastian C ; Treyer, Valérie ; O’Gorman Tuura, Ruth L ; Meier, Josefine ;
Ametamey, Simon M ; Buck, Alfred ; Landolt, Hans-Peter
Abstract: Sleep and brain glutamatergic signaling are homeostatically regulated. Recovery sleep follow-
ing prolonged wakefulness restores efficient functioning of the brain, possibly by keeping glutamatergic
signaling in a homeostatic range. Evidence in humans and mice suggested that metabotropic glutamate
receptors of subtype-5 (mGluR5) contribute to the brain’s coping mechanisms with sleep deprivation.
Here, proton magnetic resonance spectroscopy in 31 healthy men was used to quantify the levels of gluta-
mate (Glu), GLX (glutamate-to-glutamine ratio) and GABA (฀-amino-butyric-acid) in basal ganglia (BG)
and dorsolateral prefrontal cortex on 3 consecutive days, after 8 (baseline), 32 (sleep deprivation) and
8 hours (recovery sleep) of wakefulness. Simultaneously, mGluR5 availability was quantified with the
novel radioligand for positron emission tomography, [18F]PSS232, and the blood levels of the mGluR5-
regulated proteins, fragile-X mental retardation protein (FMRP) and brain-derived neurotrophic factor
(BDNF) were determined. The data revealed that GLX (p = 0.03) in BG (for Glu: p < 0.06) and
the serum concentration of FMRP (p < 0.04) were increased after sleep loss. Other brain metabolites
(GABA, N-acetyl-aspartate, choline, glutathione) and serum BDNF levels were not altered by sleep de-
privation (pall > 0.6). By contrast, the night without sleep enhanced whole-brain, basal ganglia and
parietal cortex mGluR5 availability which was normalized by recovery sleep (pall < 0.05). The findings
provide convergent multimodal evidence that glutamatergic signaling is affected by sleep deprivation and
recovery sleep. They support a role for mGluR5 and FMRP in sleep-wake regulation and warrant further
studies to investigate their causality and relevance for regulating human sleep in health and disease.
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Sleep and brain glutamatergic signaling are homeostatically regulated. Recovery sleep 
following prolonged wakefulness restores efficient functioning of the brain, possibly by 
keeping glutamatergic signaling in a homeostatic range. Evidence in humans and mice 
suggested that metabotropic glutamate receptors of subtype-5 (mGluR5) contribute to the 
brain's coping mechanisms with sleep deprivation. Here, proton magnetic resonance 
spectroscopy in 31 healthy men was used to quantify the levels of glutamate (Glu), GLX 
(glutamate-to-glutamine ratio) and GABA (γ-amino-butyric-acid) in basal ganglia (BG) and 
dorsolateral prefrontal cortex on 3 consecutive days, after ~ 8 (baseline), ~ 32 (sleep 
deprivation) and ~ 8 hours (recovery sleep) of wakefulness. Simultaneously, mGluR5 
availability was quantified with the novel radioligand for positron emission tomography, 
[18F]PSS232, and the blood levels of the mGluR5-regulated proteins, fragile-X mental 
retardation protein (FMRP) and brain-derived neurotrophic factor (BDNF) were determined. 
The data revealed that GLX (p = 0.03) in BG (for Glu: p < 0.06) and the serum concentration 
of FMRP (p < 0.04) were increased after sleep loss. Other brain metabolites (GABA, N-
acetyl-aspartate, choline, glutathione) and serum BDNF levels were not altered by sleep 
deprivation (pall > 0.6). By contrast, the night without sleep enhanced whole-brain, basal 
ganglia and parietal cortex mGluR5 availability which was normalized by recovery sleep 
(pall < 0.05). The findings provide convergent multimodal evidence that glutamatergic 
signaling is affected by sleep deprivation and recovery sleep. They support a role for mGluR5 
and FMRP in sleep-wake regulation and warrant further studies to investigate their causality 
and relevance for regulating human sleep in health and disease. 
 
















































































































Clinical Trial Registration: www.clinicaltrials.gov (study identifier: NCT03813082) 
 
Statement of Significance 
The molecular substrates of increased sleep need and intensity after prolonged wakefulness - 
referred to as sleep homeostasis - are currently unknown. The glutamatergic system has 
recently moved to center stage in the search for the molecules underlying sleep homeostasis, 
yet the evidence is virtually limited to preclinical studies. By combining multi-modal brain 
imaging (simultaneous proton magnetic resonance spectroscopy and positron emission 
tomography) and blood sampling, we demonstrate convergent changes in different markers of 
glutamatergic signaling across prolonged wakefulness and recovery sleep in humans. The 
findings suggest that glutamatergic signaling in distinct regions of the human brain play an 
important role in sleep homeostasis and highlight the possible importance of sleep in 

















































































































Sleep has been conserved throughout evolution and is generally assumed to fulfill vital 
biological functions. This notion is corroborated by the general principle referred to as sleep 
homeostasis, which assumes that the lack of sleep is predictably compensated by increased 
sleep need and intensity as reflected by electroencephalographic (EEG) slow-wave activity 
(SWA; activity in the ~ 0.75-4.5 Hz range) in non-rapid-eye-movement (NREM) sleep.1 
Prevailing current hypotheses posit that sleep homeostasis serves the normalization of 
synaptic long-term potentiation (LTP) occurring during wakefulness, by synaptic long-term 
depression (LTD) occurring during NREM sleep.2–4 
Glutamate (Glu) plays an essential role in the fine-tuned molecular processes underpinning 
LTP and LTD.5–7 Overstimulation of metabotropic and ionotropic Glu receptors by excess 
extracellular Glu is a major culprit of neuronal excitotoxicity and contributes to 
neuropsychiatric and neurodevelopmental disorders that can be exacerbated by inadequate 
sleep.8–10 Suggesting an important contribution of glutamatergic signaling to sleep 
homeostasis and a role for sleep in keeping extracellular Glu in a homeostatic range, Glu 
levels in the frontal cortex of freely moving rats rose during prolonged wakefulness and 
rapid-eye-movement (REM) sleep and decreased during NREM sleep.11 No comparable data 
are currently available in humans. 
Nevertheless, two key players were recently identified that may orchestrate synaptic plasticity 
and glutamatergic signaling across the sleep-wake cycle: Homer1a and metabotropic Glu 
receptors of subtype-5 (mGluR5). Homer1a uncouples mGluR5 from their downstream 
signaling partners, which leads to synaptic LTD.12–14 Biochemical, proteomic and imaging 
studies in mice demonstrated that Homer1a and signaling from group-I mGluRs (mGluR1/5) 
drive the homeostatic downscaling of excitatory synapses during sleep.15 In humans, mGluR5 















































































































increased after prolonged wakefulness.16 Furthermore, increased mGluR5 availability 
correlated with behavioral and neurophysiological markers of elevated sleep need, including 
self-rated sleepiness, unintended sleep during prolonged wakefulness, as well as SWA and 
slow (< 1 Hz) oscillatory activity in the NREM sleep EEG.16,17 
Apart from interacting with Homer1a, activation of mGluR5 regulates the expression of 
fragile X mental retardation protein (FMRP) and brain-derived neurotrophic factor (BDNF), 
which both play important roles in neuronal plasticity.5,18–23 Work in Drosophila suggested 
that the dFmr1 gene is a molecular regulator of sleep need,24 and that the expression of 
FMRP controls sleep time and the sleep loss-induced sleep rebound.25 Similarly, the 
expression of BDNF protein in mice has been associated with the rebound in SWA following 
sleep deprivation.26 Whereas the effects of prolonged waking on the concentration of FMRP 
in humans are unknown, for BDNF either an increase or a decrease have been reported.27,28 
Based upon the evidence outlined above, in this study in healthy human volunteers dynamic 
changes in brain metabolites, including GLX, Glu and GABA (γ-amino-butyric-acid), were 
quantified in dorso-lateral prefrontal cortex (dlPFC) and basal ganglia (BG) simultaneously 
with cerebral mGluR5 availability, as well as FMRP and BDNF levels in blood serum after 
prolonged wakefulness and following recovery sleep. It was hypothesized that sleep loss 
increases these potential markers of elevated sleep need and expected that recovery sleep 
normalizes the waking induced changes. With the exception of BDNF and GABA, all 
markers quantified revealed sleep loss-induced changes and in part reverted to baseline 
following recovery sleep, suggesting that glutamatergic signaling involving mGluR5 
contributes to the regulation of sleep-wake dependent synaptic plasticity in humans. 
 















































































































To visualize the interplay of mGluR5 with its potential molecular signaling partners in sleep-
wake regulation, a controlled in-lab study was designed, in which 3-Tesla PET/MR-
Spectroscopy scanning and blood sampling were conducted three times, at the same circadian 
time in baseline, after a night without sleep, and again following recovery sleep. 
Concentrations of glutamate, the glutamate/glutamine (GLX) ratio and γ-amino-butyric acid 
(GABA) in basal ganglia (BG) and dorsolateral prefrontal cortex (dlPFC) were measured 
with dedicated PRESS/MEGAPRESS MRS sequences. The mGluR5 availability was 
quantified with the novel PET radioligand [18F]PSS232 which is a non-competitive selective 
antagonist of mGluR5.29,30 Circulating levels of BDNF and FMRP in human blood were 
quantified with ELISA. 
 
Study Participants 
The study protocol and all experimental procedures were approved by the ethics committee 
of the Canton of Zürich for research on human subjects. All subjects provided written 
informed consent prior to the experiments and received financial compensation for their 
participation, in accordance with the principles in the Declaration of Helsinki. 
Thirty-one healthy men completed a within-subject, 1-week sleep deprivation protocol after 
being screened for medical history and psychological state. All subjects were non-smokers, in 
good health, had no history of neurologic or psychiatric disease and were instructed not to 
take any medications or consumed any illicit drugs 2 months prior to the study. Subjects were 
excluded if they traveled across multiple time zones or performed shift work 3 months prior 
to study participation. Subjects who prior to the study were not aware of the presence of any 
sleep-wake disturbances, yet the polysomnographic screening night in the sleep laboratory 















































































































(PLMS) with an index of 5 or more per hour of sleep, were excluded from participation and 
study enrolment. Table 1 summarizes lifestyle and demographic characteristics of the healthy 
study sample assessed by validated questionnaires. 
Validated German translations and versions of questionnaires were used to assess lifestyle 
and personality traits. Caffeine consumption was calculated based on the following amounts 
per serving: coffee: 100 mg; ceylon or green tea: 30 mg; cola drink: 40 mg (2 dL); energy 
drink: 80 mg (2 dL); chocolate: 50 mg (100 g). Diurnal preference: Horne-Östberg 
Morningsness-Eveningness Questionnaire;31 daytime sleepiness: Epworth Sleepiness Scale;32 
depression score: Beck Depression Inventory;33 personality traits: Eysenck Personality 
Questionnaire;34 cognitive assessment: Montreal Cognitive Assessment;35 trait anxiety: State-
Trait Anxiety Inventory;36 sleep quality: Pittsburgh Sleep Quality Index.37 
 
Pre-experimental Procedure and Experimental Protocol 
Two weeks prior to the study, participants were required to refrain from all sources of 
caffeine and wear a wrist activity monitor on the non-dominant arm. During the 5 days prior 
to the study they were asked to abstain from alcohol intake and to maintain a regular 8-hour 
night-time sleep schedule, corresponding approximately to the participants’ habitual sleep 
times. Daily log-books and wrist actigraphy verified compliance with the pre-study 
instructions. Additionally, caffeine and ethanol concentrations in saliva and breath were 
tested upon entering the laboratory, to confirm participants’ abstinence. 
Under constant supervision, all subjects completed a within-subject sleep deprivation 
protocol (Fig. 1), consisting of an 8 hours adaptation and baseline night (time in bed: 
11:00PM-07:00AM), followed by 40 hours of continuous wakefulness, and terminated by a 10-















































































































22 subjects underwent a combined positron emission tomography (PET) with [18F]PSS232 to 
quantify mGluR5 availability in the brain and proton magnetic resonance spectroscopy (1H-
MRS) examination (Division of Nuclear Medicine, University Hospital Zürich). To minimize 
confounding circadian effects, all measurements were conducted at the same circadian 
timepoint, starting at 4:23PM ± 23 min. Due to time and logistic constraints, only two subjects 
could be PET scanned per experimental week. To optimize data collection, one additional 
subject was included in each study block (n = 9 in total) as a back-up candidate, participating 
in the entire experimental protocol, MR imaging and blood sampling, but without 
[18F]PSS232 injection and PET scanning. 
 
Magnetic Resonance Spectroscopy data acquisition and analysis 
The 1H-MRS data were acquired simultaneously with the PET data using a GE 3T combined 
PET/MR scanner (SIGNA PET/MR; GE Healthcare). Single-voxel edited 1H-MR spectra 
were acquired from two voxels of interest in the left dorsolateral prefrontal cortex (dlPFC; 30 
x 25 x 40 mm3) and in the basal ganglia (BG; 35 x 30 x 25 mm3) using the MEshcher-
GArwood Point RESolved Spectroscopy (MEGAPRESS) method to quantify GABA as well 
as Glx and Glu.38 In addition, a third voxel of interest (VOI) in the BG (25 x 25 x 25 mm3) 
was measured with the Point RESolved Spectroscopy (PRESS) method to quantify just Glx 
and Glu.38 To ensure a consistent MRS voxel position between subjects, the voxel was 
carefully positioned based on anatomical landmarks on the T1 image. The T1 weighted MR 
images were also used to correct for partial volume effects related to the cerebrospinal fluid 
(CSF) content in the MRS voxel, as well as for gray/white matter correction. 
MEGAPRESS: A total of 320 spectra were averaged to obtain the final spectrum. Individual 















































































































cycle, resulting in a total acquisition time of ~10 minutes. For each metabolite spectrum, 16 
water reference lines were also acquired as part of the standard PROBE acquisition. 
PRESS: The PRESS spectra were acquired with an echo time (TE) of 35 ms and a repetition 
time (TR) of 3 ms. 160 spectral averages were acquired to obtain the final spectrum resulting 
in an acquisition time of 9 min. 
 
Data analysis 
The MR spectra were analyzed with LCModel v. 6.3-1,39 which is a fully automated spectral 
fitting method. For the MEGAPRESS data, edited spectra were analyzed with a simulated 
basis set providing metabolite concentrations for glutamine (Gln), glutamate (Glu), glutamate 
to glutamine (GLX), GABA, N-acetylaspartate, and glutathione. The control parameter 
sptype = ‘megapress-2’ was used to avoid mis-assignment of the baseline to GABA. For the 
PRESS spectra, a standard experimental basis set was used, from which data for creatine, 
glutamate to glutamine, myo-inositol, N-acetyl-aspartate, and total choline were extracted 
(Supplementary Figure S1). For all spectra, peaks that were poorly fitted, resulting in 
Cramer-Rao minimum variance bounds of more than 20% as reported by LCModel or 
demonstrating apparent artefacts were excluded from further analyses. Specifically, six 
dlPFC spectra from 5 participants could not be included in the statistical analyses. Moreover, 
some basal ganglia spectra measured with PRESS were unfortunately automatically 
overwritten by the scanner software, resulting in missing data points. The numbers of 
included subjects are indicated throughout the results and in all graphs and/or legends to the 
Figures. 
 















































































































A T1-weighted, whole-brain, three-dimensional magnetic resonance (MR) image (resolution: 
1 x 1 x 1 mm) was obtained for each subject in parallel to the PET imaging (SIGNA PET/MR 
3T whole-body PET/MR unit equipped with an 8-channel head coil; GE Healthcare), to 
exclude morphological abnormalities and as anatomical standard for the quantification of the 
PET images. After an automated standard single bolus injection of [18F]PSS232, dynamic 
PET brain imaging was performed for 60 min. Images were acquired in 3D Mode with Time 
of flight fully iterative reconstruction (VPFX) using standard MRAC based attenuation 
correction with a resolution of 1.17 x 1.17 x 2.78 mm3 and Matrix size of 256 x 256 x 89 
voxels binned into 43 timeframes (11 x 1 min, 22 x 2 min, 10 x 1 min). Subjects were 
instructed to not fall asleep during image acquisition. To verify wakefulness, subjects were 
instructed to gently press the button of a response box, generating as little movements as 
possible. As soon as subjects stopped pressing the response box, subjects were alerted via an 
intercom. Direct contact was avoided, to minimize movement artifacts. Due to technical 
issues with tracer synthesis, some subjects were not scanned in sleep deprivation and 
recovery conditions, resulting in missing data points. 
Neither injected tracer activity (BL: 164.7 ± 5.2 MBq; TSD: 159.1 ± 3.6.9 MBq; RE: 154.7 ± 
3.1 MBq; p > 0.32, factor ‘condition’), total activity at the end of synthesis (BL: 2.16 ± 0.10 
GBq; TSD: 2.15 ± 0.14 GBq; RE: 1.86 ± 0.12 GBq; p > 0.23), nor injected patient dose of 
[18F]PSS232 (BL: 2.00 ± 0.22 mg; TSD: 1.55 ± 0.17 mg; RE: 1.75 ± 0.16 mg; p > 0.18) 
differed between the conditions. 
 
Image processing and quantification 
All processing and quantification analyses were conducted with a dedicated brain PET/MR 















































































































processing consisted of within-subject rigid-body motion correction followed by time-series 
alignment to the MR-T1 image for between scan comparisons. For PET quantification, the T1 
image was automatically segmented, separating the MR image into gray matter (GM), white 
matter (WM) and CSF probability maps. After matching the T1 MR image to the functional 
PET images, the specific neocortical and subcortical (core brain segments) brain regions were 
determined using the Hammers-N30R83 brain atlas. Partial volume correction (PVC) was 
performed automatically in the PNEURO toolbox. A time activity curve (TAC) was 
calculated for each VOI. Because a single bolus injection was used, the binding potential 
(BPND) was quantified with standard SRTM2 [Simplified Reference Tissue Model with fixed 
k2;40] modelling. For modelling, TACs of receptor-rich regions (gray matter VOIs) were 
compared to the TAC of a receptor-less region (cerebellum) believed mainly to entail non-
specific binding.30 
 
Assessment of proteins in human serum 
Fresh blood was collected immediately before the PET/MRS scans in two 10ml clot activator 
tubes (BD Vacutainer® CAT). The samples were allowed to clot for about 30 minutes at room 
temperature (RT) before centrifugation (2.000 relative centrifugal force (RCF) for 10 min). 
1.9 mL serum was extracted and purified by a second centrifugation step (12.000 RCF for 5 
minutes). The purified serum was aliquoted into multiple 255μ1 samples and stored in 
Eppendorf tubes (SafeSeal micro tube 1.5 ml, PP, Sarstedt, Nümbrecht) The probes were then 
snap-frozen in liquid nitrogen and stored at -80°C for future analysis. 
 















































































































FMRP was studied by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) 
purchased prefabricated and ready to use (Human Fragile X mental retardation 1 ELISA kit, 
MyBioSource, San Diego, California USA). The detection rate of this assay is 15.6 – 1000 
pg/ml. A 96-well microplate was pre-coated with a FMRP-specific antibody. Each sample 
was quantified at least twice for independent confirmation according to the manufacturer’s 
instructions and guidelines (coefficients of inter-assay variation: BN: CV = 14.23 ± 1.52 %, 
TSD: CV = 11.39 ± 1.68 %, RE: CV = 13.52 ± 1.37 %). The data were normally distributed 
(D = 0.08, Pr > D > 0.15, Kolmogorov–Smirnov) and sleep deprivation and recovery sleep 
did not affect the number of monocytes per ml of blood sample used for FMRP analyses (p > 
0.69). For technical reasons, some samples could not be reliably quantified and were 
excluded from the analyses. 
 
Brain-derived neurotrophic factor (BDNF) 
Quantification of serum BDNF levels was conducted at the Department of Clinical 
Psychology and Psychotherapy at the University of Zurich using a 96-Well MULTI-
ARRAY® BDNF Assay purchased from Meso-Scale Discovery (MSD®, Rockville, 
Maryland USA), according to the manufacturer’s instructions. No estimate of coefficients of 
inter-assay variation could be obtained. 
 
Statistical Analyses 
All statistical analyses were performed with SAS 9.4 software (SAS Institute, Cary, North 
Carolina). If not stated otherwise, numbers represent mean ± standard error of the mean 
(SEM) and the error bars shown in the figures represent the SEM of between-subjects 















































































































protein, PET and 1H-MRS data included the within-subjects factor ‘condition’ (BL, TSD, RE; 
supplementary Table S2). The p-values of post-hoc analyses to localize significant 
differences between the experimental conditions were corrected as follows: Base upon a 
priori hypotheses, the statistical analyses of global mGluR5 availability and FMRP and 
BDNF levels consisted of three-condition (BL, TSD, RE) Tukey-Kramer correction. The 
secondary analyses including 81 comparisons (15 pre-selected PET VOIs across 3 conditions 
and 6 MRS metabolites in 2 brain regions across 3 conditions) were corrected by the 
Benjamini-Hochberg procedure to reduce the false discovery rate. If not mentioned 
otherwise, only findings with a corrected p-value below the threshold of α < 0.05 were 
considered significant (supplementary Table S3). Following significant main effects of 
‘condition’ and post-hoc testing, Mann-Whitney U tests of the relative data were performed 
to illustrate the individual differences in the % change due to the experimental interventions. 
 
Results 
Thirty-one healthy men completed this strictly controlled study (Table 1 for demographics; 
the numbers of study participants contributing to each analysis are specified below). 
Following 8-hour adaptation and baseline sleep opportunities in the sleep laboratory, all 
volunteers stayed awake under constant supervision for 40 hours, followed by a 10-hour 
recovery sleep opportunity. All measurements in BL, TSD and RE started at the same 
circadian time, at 4:23 pm ± 23 min (Fig. 1). The prolongation of wakefulness increased 
subjective sleepiness and symptoms of tiredness and lowered the levels of mood and energy. 
Recovery sleep reversed these changes in subjective state (supplementary Table S1). 
 















































































































Methodological advances in 1H-MRS have recently permitted the non-invasive detection of 
naturally occurring changes in tightly regulated metabolite concentrations in circumscribed 
areas of the human brain. Whereas one recent study suggested that GLX levels in the left 
parietal lobe decrease over night,41 previous data from this lab revealed no significant 
changes after sleep deprivation in GLX/Glu and GABA in the medial prefrontal cortex.17 
Thus, the exact roles in humans of the main excitatory and inhibitory neurotransmitters in 
circadian and homeostatic sleep-wake regulation remain unclear. Here, the effects of 
prolonged wakefulness and recovery sleep on the extracellular concentrations of Glu, GLX 
and GABA in two pre-defined voxels located in cortex (dlPFC) and BG were quantified at 
the same circadian time in a separate study in 31 newly recruited study participants. Both 
these regions show pronounced waking-induced changes in mGluR5 availability,17 and are 
thought to contribute importantly to sleep homeostasis.42–44 Consistent with our previous 
study,17 sleep deprivation caused no reliable changes in these metabolites in the cortex (Fig. 
2, left-hand panel). By contrast, Glu levels in the BG were increased after prolonged waking 
in 17 of 21 study participants when compared to baseline (Fig. 2, right-hand panel). The 
mean increase equaled 6.31 ± 2.06 %, which tended to be significant (BL: 1.41 ± 0.02 
[arbitrary units]; TSD: 1.50 ± 0.03; TSD vs. BL: p < 0.06, n = 21). Similarly, sleep loss 
increased the GLX concentration in the BG in 16 of 21 subjects, and the mean increase 
equaled 9.02 ± 2.53 % (BL: 1.66 ± 0.04; TSD: 1.81 ± 0.05; TSD vs. BL: p < 0.04, n = 21). 
When relative changes were analyzed, a sleep deprivation-induced increase in both Glu and 
GLX levels in the BG was confirmed (p < 0.01, Mann-Whitney U tests). Although both, Glu 
(TSD: 1.50 ± 0.03; RE: 1.45 ± 0.03; RE vs. TSD: 2.8 % reduction) and GLX (TSD: 
1.81 ± 0.05; RE: 1.73 ± 0.04; RE vs. TSD: 4.2 % reduction) were slightly reduced after 
















































































































The levels of GABA remained stable in the BG following sleep deprivation and recovery 
sleep (BL: 0.45 ± 0.01; TSD: 0.45 ± 0.007; RE: 0.41 ± 0.01; TSD vs. BL: p > 0.8; RE vs. 
TSD: p > 0.9, n = 21) (Fig. 2C). Similarly, no significant changes in other metabolites (N-
acetylaspartate, glutathione, choline) were detected (supplementary Table S3). 
 
Whole-brain mGluR5 availability is elevated after sleep deprivation and normalized after 
recovery sleep 
To quantify sleep-wake associated changes in the availability of mGluR5 that may occur 
simultaneously with the above described local changes in Glu, GLX and GABA, the newly 
developed, highly selective, non-competitive mGluR5 antagonist for PET brain imaging, 
[18F]PSS232, was employed.29,30 
When compared to baseline, sleep deprivation induced a consistent increase in whole-brain 
[18F]PSS232 binding potential reflecting elevated cerebral mGluR5 availability (BL: 
1.16 ± 0.04; TSD:1.20 ± 0.04; TSD vs. BL: p < 0.05, n = 20) (Fig. 3). The [18F]PSS232 
binding increased from BL to TSD in 15 of 20 subjects in whom PET scans in both 
conditions were available. On average, the sleep deprivation-induced increase in whole-brain 
mGluR5 availability equaled 5.53 ± 2.22 %. 
To examine whether recovery sleep reverses the wakefulness-induced changes, PET scans 
were also performed after the recovery night. In 13 of 16 study participants in whom TSD 
and RE data were available, whole-brain [18F]PSS232 binding was reduced in RE when 
compared to TSD (TSD: 1.21 ± 0.05; RE: 1.14 ± 0.04; RE vs. TSD: p < 0.01, n = 16). The 
reduction in mGluR5 availability from TSD to RE equaled 5.77 ± 1.50 %. No difference in 
[18F]PSS232 binding potential between BL and RE was detected, suggesting that recovery 
















































































































Wake-sleep dependent changes in mGluR5 availability in basal ganglia, amygdala and 
parietal cortex 
Fourteen VOIs previously associated with sleep-wake regulation 16,17,67 were selected for 
secondary PET image analyses. These VOIs included: caudate nucleus, putamen, ventral 
striatum, amygdala, dlPFC, orbitofrontal cortex, medial superior frontal cortex, anterior 
cingulate cortex, parietal cortex, inferior parietal cortex, precuneus, medial temporal lobe, 
parahippocampal gyrus, hippocampus and insula. Increased [18F]PSS232 binding after 
prolonged waking was observed in caudate nucleus (BL: 1.15 ± 0.06; TSD: 1.25 ± 0.06; 
increase: 8.71 ± 4.82 %; TSD vs. BL: p < 0.03) and parietal cortex (BL: 1.12 ± 0.05; TSD: 
1.19 ± 0.05; increase: 6.58 ± 4.46 %; TSD vs. BL: p < 0.03), and tended to be increased in the 
amygdala (BL: 1.27 ± 0.07; TSD: 1.38 ± 0.07; increase: 8.66 ± 4.72 %; TSD vs. BL: 
p < 0.06; n = 20) (supplementary Table S3). When relative changes were analyzed, an 
increase in mGluR5 availability by sleep deprivation was present in all these three brain 
regions (Fig. 4, lower panel). Similar to the whole-brain data, recovery sleep normalized 
mGluR5 availability in caudate nucleus (TSD: 1.25 ± 0.06; RE: 1.14 ± 0.06; reduction: 
8.59 ± 3.46 %; RE vs. TSD: p < 0.03), amygdala (TSD: 1.38 ± 0.07; RE: 1.23 ± 0.07; 
reduction: 11.31 ± 4.71 %; RE vs. TSD: p < 0.03) and parietal cortex (TSD: 1.19 ± 0.05; RE: 
1.13 ± 0.05; reduction: 5.51 ± 1.95 %; RE vs. TSD: p < 0.03; n = 16) to the level of baseline 
(RE vs. BL: pall > 0.5, n = 16) (Fig. 4). 
 
Sleep deprivation increases FMRP concentration in blood serum 
To tackle the question whether the wake-sleep-related changes in Glu/GLX concentrations 















































































































in peripheral blood, circulating FMRP and BDNF in serum were quantified with enzyme-
linked immunosorbent assays (ELISA) in BL, TSD and RE conditions. Intriguingly, 
prolonged waking increased the blood FMRP concentration in 13 of 23 subjects (BL: 
268.52 ± 33.76 pg/ml; TSD: 370.86 ± 31.93 pg/ml; mean increase: 25.86 ± 16.39 %, TSD vs. 
BL: p < 0.04, n = 23) (Fig. 5). Although the FMRP concentration in RE tended to revert to 
baseline and the mean FMRP levels in these two conditions did not differ, a difference was 
neither observed between RE and TSD conditions (RE: 333.89 ± 33.51 pg/ml; RE vs. BL: 
p > 0.25, n = 21; RE vs. TSD: p > 0.6, n = 23). 
In contrast to FMRP, the levels of BDNF were not affected by prolonged waking 
(supplementary Figure S2). 
 
Discussion 
Glutamate is the primary excitatory neurotransmitter of the human brain. Although basic 
research in vitro and in animal models highlights a prominent role for glutamatergic 
mechanisms in regulating sleep-wake homeostasis,11,15,17,46–48 knowledge about glutamatergic 
signaling as a function of waking and sleep in humans is scarce. This study suggests an 
important relationship between glutamatergic signaling and sleep in humans and supports a 
role of the basal ganglia in sleep homeostatic mechanisms. More specifically, the data 
revealed that one night without sleep elicited reliable increases in cerebral Glu/GLX levels 
and mGluR5 availability, particularly in the basal ganglia, as well as in the concentration of 
the mGluR5-regulated protein, FMRP, in the blood stream. Given that most of these 
wakefulness-induced molecular changes tended to normalize after recovery sleep, the 
findings suggest that sleep may be beneficial to keep glutamatergic signaling in a homeostatic 















































































































degeneration, which can be caused by excessive glutamate,8–10 on multiple levels of the 
metabotropic glutamatergic signaling cascade. Nevertheless, because the concentrations of 
Glu/GLX and FMRP were not fully restored by recovery sleep, a single recovery night is 
probably insufficient for the glutamatergic system to fully recover after a night of total sleep 
deprivation. 
 
Sleep deprivation and recovery sleep induce dynamic changes in basal ganglia glutamate 
levels 
The levels of glutamate in the rat cortical extra-synaptic space rise during waking and 
decrease during NREM sleep,11 yet it is currently unknown whether similar changes also 
occur in the human brain. To examine a glutamatergic contribution to the relief of depressive 
symptoms after wake therapy, brain levels of Glu, GLX and GABA were previously 
measured with 1H-MRS in depressed patients undergoing acute and repeated therapeutic 
sleep deprivation.49–51 No significant alterations in GLX or its elements were found in 
different cortical regions (dlPFC, anterior cingulate cortex and parieto-occipital cortex), yet 
preliminary data indicated that sleep loss increased GLX in subcortical brain regions.49 
Because the baseline levels of GLX and Glu in cerebral cortex differ between depressed 
patients and healthy controls,52,53 it is unclear whether these older studies are directly 
comparable with the present investigation. Nevertheless, previous17 and current work in 
healthy controls is consistent with the data in depressed patients.50,51 It indicates that 
prolonged wakefulness does not reliably alter the MRS signal compatible with GLX and its 
constituents in anterior cingulate cortex and dlPFC. It cannot be excluded, however, that the 
lack of a significant change in GLX in the dlPFC voxel could be related to the voxel 
composition, which, compared to the basal ganglia voxel was composed of a higher fraction 















































































































The data collected in the BG strongly suggest that sleep loss indeed affects glutamatergic 
signaling on different levels. More specifically, prolonged wakefulness increased Glu, GLX 
and mGluR5 availability in sub-regions of the basal ganglia, and some of these changes were 
re-normalized after recovery sleep. The findings corroborate and expand previously 
published observations from this group, showing that mGluR5 availability was increased 
after sleep deprivation.16 The investigation of different brain regions indicated that the basal 
ganglia are a brain structure that reliably shows sleep-wake related changes in the 
glutamatergic balance in humans. The dorsal (caudate nucleus and putamen) and ventral 
(nucleus accumbens and olfactory tubercle) parts of the striatum and the amygdala showed 
increased mGluR5 availability after sleep loss.16 Together, the data strengthen the emerging 
hypothesis that the basal ganglia are a key player in sleep-wake regulation.54–56 Whereas the 
observed increase by 5-10 % in Glu levels and mGluR5 availability after extended 
wakefulness may be considered as small or moderate, the simultaneous changes could 
mutually amplify each other and cause a substantial increase in glutamatergic signaling after 
sleep deprivation. Importantly, the present new data demonstrate that recovery sleep is 
associated with reduced mGluR5 availability, supporting a restorative role for sleep and 
providing complementary evidence for the mGluR5 signaling cascade to contribute to sleep-
wake regulation. 
 
Sleep deprivation impacts on the expression of FMRP 
Currently the most specific molecular marker of sleep need is the immediate early gene 
Homer1a,46,57 which uncouples mGluR5 from its downstream signaling partners, leading to 
synaptic long-term depression.12–15,58 This form of synaptic plasticity may ultimately support 
sleep dependent recovery processes.15,59,60 The mGluR5 has been specifically associated with 















































































































with experiments in Drosophila,24 the present data reveal elevated FMRP levels after 
prolonged wakefulness when compared to baseline. A prolonged effect of sleep deprivation, 
or insufficient recovery sleep, might explain the incomplete normalization in some 
measurements after recovery. In contrast to the findings in vivo, the FMRP concentration in 
cultured neural cells of sleep deprived rats appeared to decrease with sleep deprivation.61 
Further research is needed to clarify the potential role for FMRP in sleep-wake regulation. 
Moreover, the concentration of FMRP in human blood serum is low (in the pg range), 
rendering its quantification difficult, and depends on various possible factors, including 
genetic.68 Cautious interpretation and independent replication of this result are, thus, crucial. 
Similarly, the evidence for a suggested role of BDNF in regulating sleep homeostasis and 
LTP-like plasticity after sleep deprivation has been equivocal.28,62 Here, neither sleep 
deprivation nor recovery sleep revealed consistent effects on BDNF levels in the human 
serum as quantified with ELISA. The establishment of a reliable method to assess blood 
serum BDNF still remains a clinical challenge. The discrepancies among the available studies 




Although the findings cannot be generalized to female and patient populations because only 
healthy men were investigated, this study provides convergent evidence that sleep deprivation 
and recovery sleep affects glutamatergic signaling in distinct regions of the human brain that 
play an important role in sleep-wake regulation. Nevertheless, the questions remain whether 
the observed molecular changes regulate the need for sleep or whether they reflect secondary 















































































































findings warrant further studies to elucidate the mechanisms that link the homeostatic 
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Values represent means ± SD (n = 31). Caffeine consumption was calculated based on the 
following amounts per serving: coffee: 100mg; ceylon or green tea: 30 mg; cola drink: 40 mg 
(2 dL); energy drink: 80 mg (2 dL); chocolate: 50 mg (100 g). Diurnal preference: Horne-
Östberg Morningsness-Eveningness Questionnaire (Horne et al., 1976); daytime sleepiness: 
Epworth Sleepiness Scale (Bloch et al., 1999); depression score: Beck Depression Inventory 
(Beck et al., 1961); personality traits: Eysenck Personality Questionnaire (Francis et al., 
2006); cognitive assessment: Montreal Cognitive Assessment (Nasreddine, 2005); trait 
anxiety: State-Trait Anxiety Inventory (Spielberger et al., 1970); sleep quality: Pittsburgh 
Sleep Quality Index (Buysse et al., 1989). 
 
Demographic variable  
Age (years) 41.44 ± 20.86 
Body Mass Index (kg/m2) 23.85 ± 2.37 
Caffeine Consumption (mg/day) 176.32 ± 144.64 
Alcohol Consumption (drinks/Week) 2.98 ± 2.67 
Daytime Sleepiness  7.14 ± 3.27 
Habitual Sleep Duration (h) 7.44 ± 0.55 
Sleep Quality 3.05 ± 1.46 
Diurnal Preference  56.00 ± 10.31 
Trait Anxiety  29.68 ± 7.55 
Eysenck Personality Traits 
 Psychoticism 1.95 ± 1.68 
 Extraversion 7.32 ± 3.40 
 Neuroticism 2.18 ± 2.68 
 Lie scale 3.68 ± 2.51 
Depression Score  3.45 ± 4.64 
















































































































Figure 1. Experimental protocol. After an adaptation and baseline night, subjects 
underwent 40hrs of prolonged wakefulness followed by a recovery night. At baseline (BL), 
after sleep deprivation (TSD), and again after recovery sleep (RE), levels of mGluR5 were 
measured using positron emission tomography with [18F]PSS232 at the same circadian 
timepoint (blue dotted lines). Furthermore, distinct brain metabolites were measured with 
magnetic resonance spectroscopy and blood samples for the quantification of blood BDNF 
and FMRP levels were drawn at these timepoints. Blue box summarizes type of data 
collection and number of subjects at the imaging sessions in BL, TSD and RE conditions 
(blue dotted lines). A cognitive test session was performed every three hours of wakefulness 
consisting of vigilance (Psychomotor Vigilance Task [PVT]),63 sleepiness (Karolinska 
Sleepiness Scale [KSS]),64 tiredness symptoms (Tiredness Symptoms Scale [TSS])65 and 
affective state (Visual Analogue Scales [VAS])66 testing. 
Figure 2: Effects of sleep deprivation and recovery sleep on endogenous brain 
metabolites in dorsolateral prefrontal cortex (dlPFC, left) and basal ganglia (BG, right). 
Magnetic resonance spectroscopy yielded levels of glutamate (Glu; A), glutamate/glutamine 
ratio (Glx; B) and γ-aminobutyric acid (GABA; C) relative to creatine in baseline (BL, dark 
grey), sleep deprivation (TSD, blue) and recovery (RE, light grey) conditions. Data represent 
means of arbitrary units (A.U.) ± standard error of the mean (SEM). Numbers on the bars 
indicate the number of contributing individuals. Black dots represent individual subjects. 
Missing data points were caused by technical problems during 1H-MRS quantification. Data 
for Glu and Glx were acquired with PRESS and data for GABA with MEGAPRESS 
sequences. p-values: Benjamini-Hochberg corrected paired, t-tests. 
Figure 3: Effects of sleep deprivation and recovery sleep on whole-brain metabotropic 















































































































potential (BPND) after [
18F]PSS232 uptake in human brain. Individual data points in baseline 
(BL, n = 22) and following total sleep deprivation (TSD, n = 20) and recovery sleep (RE, 
n = 18) are plotted. Connecting lines represent within-subjects changes from BL to TSD and 
from TSD to RE. The color code identifies individuals exhibiting an increase from BL to 
TSD (filled black circles) and individuals exhibiting a decrease from BL to TSD (filled red 
circles); filled grey circles: TSD condition missing. p-values: Tukey-Kramer corrected paired, 
t-tests following significant mixed-model ANOVA with the within-subject factor ‘condition’ 
(F2,36 = 4.52, p < 0.02). (B) Box plots of relative changes in global mGluR5 availability from 
BL to TSD, TSD to RE, and BL to RE. Black dots represent individual subjects. Asterisks 
indicate significant change scores: * = p < 0.03, ** = p < 0.01 (Mann-Whitney U tests). 
Figure 4: Regional differences in the effect of sleep deprivation and recovery sleep on 
metabotropic glutamate receptor subtype 5 (mGluR5). Upper panel: NonDisplaceable 
binding potential (BPND) after [
18F]PSS232 uptake in Caudate nucleus (A), amygdala (B) and 
parietal cortex (C). Individual data points in baseline (BL, n = 22) and following total sleep 
deprivation (TSD, n = 20) and recovery sleep (RE, n = 18) are plotted. Connecting lines 
represent within-subjects changes from BL to TSD and from TSD to RE. The color code 
identifies individuals exhibiting an increase from BL to TSD (filled black circles) and 
individuals exhibiting a decrease from BL to TSD (filled red circles); filled grey circles: TSD 
condition missing. p-values: Benjamini-Hochberg corrected paired, t-tests following 
significant mixed-model ANOVA with the within-subject factor ‘condition’ (Caudate 
nucleus: F2,36 = 6.25, p < 0.01; amygdala: F2,36 = 5.54, p < 0.01; parietal cortex: F2,36 = 6.85, 
p < 0.01). Lower panel: Box plots of relative changes in mGluR5 availability in Caudate 
nucleus (A), amygdala (B) and parietal cortex (C) from BL to TSD, TSD to RE, and BL to 
RE. Black dots represent individual subjects. Asterisks indicate significant change scores: 















































































































Figure 5: Effects of sleep deprivation and recovery sleep on serum fragile X mental 
retardation protein levels (FMRP). (A) Circulating FMRP concentration in human blood 
serum. Individual data points in baseline (BL, n = 24) and following total sleep deprivation 
(TSD, n = 27) and recovery sleep (RE, n = 26) are plotted. Connecting lines represent within-
subjects changes from BL to TSD and from TSD to RE. The color code identifies individuals 
exhibiting an increase from BL to TSD (filled black circles) and individuals exhibiting a 
decrease from BL to TSD (filled red circles); filled grey circles: TSD condition missing. 
p-values: Tukey-Kramer corrected paired, t-tests following significant mixed model ANOVA 
with the within-subject factor ‘condition’ (F2,44 = 3.37, p < 0.05). (B) Box plots of relative 
changes in blood FMRP levels from BL to TSD, TSD to RE, and BL to RE. Black dots 
















































































































List of abbreviations 
mGluR5: metabotropic glutamate receptor of subtype 5 
Glu: glutamate 
GLX: glutamate-to-glutamine ratio 
GABA: γ-amino-butyric-acid 
BG: basal ganglia 
dlPFC: dorsolateral prefrontal cortex 
FMRP: fragile-X mental retardation protein 
BDNF: brain-derived neurotrophic factor 
PET: positron emission tomography 
MRS: magnetic resonance spectroscopy 
EEG: electroencephalography 
SWA: slow-wave activity 
NREM sleep: non-rapid-eye-movement sleep 
LTP: long-term potentiation 
LTD: long-term depression 
REM sleep: rapid-eye-movement sleep 
PRESS: Point RESolved Spectroscopy 
MEGAPRESS: MEshcher-GArwood Point RESolved Spectroscopy 
ELISA: enzyme-linked immunosorbent assay 
PLMS: periodic leg movements during sleep 
SEM: standard error of the mean 
VOI: voxel of interest 
CSF: cerebrospinal fluid 
TR: repetition time 
TE: echo time 















































































































GM: gray matter 
WM: white matter 
PVC: partial volume correction 
TAC: time activity curve 
BPND: NonDisplaceable binding potential 
SRTM2: Simplified Reference Tissue Model with fixed k2 
RT: room temperature 
RCF: relative centrifugal force 
FDR: false discovery rate 
BL: baseline 
TSD: total sleep deprivation 
RE: recovery 
PVT: psychomotor vigilance task 
KSS: Karolinska sleepiness scale 
TSS: tiredness symptoms scale 
VAS: visual analogue scale 
ANOVA: Analysis of variance 
denDF: denominator degrees of freedom 
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